Shares of Structure Therapeutics (NASDAQ: GPCR) were up by more than 32% as of 12:15 p.m. ET Friday after the pharmaceutical company announced positive clinical trial results for a weight-loss therapy candidate.
Structure Therapeutics is a clinical-stage company that focuses on oral therapies to treat chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. The company said in a press release on Friday that its once-daily pill GSBR-1290 helped study participants reduce their body weights by an average of as much as 4.9 kilograms (10.8 pounds) over 28 days of treatment in a phase 1b study. The pill is a GLP-1 receptor agonist, the same class of drugs as Mounjaro from Eli Lilly and Wegovy from Novo Nordisk. However, those two therapies are injectables, while GSBR-1290 is a more easily taken pill. GLP-1 receptor agonists help the body regulate blood sugar and decrease appetite because they slow down the rate at which the stomach empties itself of food.
The company, which just went public in February, said it plans two phase 2b studies of the drug next year — one as a diabetes treatment with roughly 500 subjects, and the other as an obesity treatment with 275 subjects.
The company also announced that it had entered into a share purchase agreement worth $300 million with institutional investors. That should help the company continue the clinical trial process for GSBR-1290. As of the end of the second quarter, Structure Therapeutics had $224.6 million in cash on hand — enough, it said, to fund operations through 2025. This fundraising move expands that window a bit. Its pipeline includes three other programs besides GSBR-1290.
10 stocks we like better than Structure Therapeutics
When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now… and Structure Therapeutics wasn’t one of them! That’s right — they think these 10 stocks are even better buys.
*Stock Advisor returns as of September 25, 2023
Jim Halley has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy.
—
Blog powered by G6
Disclaimer! A guest author has made this post. G6 has not checked the post. its content and attachments and under no circumstances will G6 be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your use of or inability to use this website or any websites linked to it, or from your reliance on the information and material on this website, even if the G6 has been advised of the possibility of such damages in advance.
For any inquiries, please contact [email protected]
